These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 18634052)
1. Enhanced anti-cancer effect of a phosphatidylinositol-3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status. Wang YA; Johnson SK; Brown BL; McCarragher LM; Al-Sakkaf K; Royds JA; Dobson PR Int J Cancer; 2008 Oct; 123(7):1536-44. PubMed ID: 18634052 [TBL] [Abstract][Full Text] [Related]
2. Differential enhancement of the anti-cancer effect of doxorubicin by Akt inhibitors on human breast cancer cells with differing genetic backgrounds. Wang YA; Johnson SK; Brown BL; Dobson PR Oncol Rep; 2009 Feb; 21(2):437-42. PubMed ID: 19148520 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression. McDonald GT; Sullivan R; Paré GC; Graham CH Exp Cell Res; 2010 Nov; 316(19):3197-206. PubMed ID: 20736003 [TBL] [Abstract][Full Text] [Related]
4. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines. Badinloo M; Esmaeili-Mahani S Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575 [TBL] [Abstract][Full Text] [Related]
5. Differential regulation of signal transduction pathways in wild type and mutated p53 breast cancer epithelial cells by copper and zinc. Ostrakhovitch EA; Cherian MG Arch Biochem Biophys; 2004 Mar; 423(2):351-61. PubMed ID: 15001399 [TBL] [Abstract][Full Text] [Related]
6. The PI3K inhibitor LY294002 prevents p53 induction by DNA damage and attenuates chemotherapy-induced apoptosis. Bar J; Lukaschuk N; Zalcenstein A; Wilder S; Seger R; Oren M Cell Death Differ; 2005 Dec; 12(12):1578-87. PubMed ID: 15933740 [TBL] [Abstract][Full Text] [Related]
7. Growth factors and chemotherapeutic modulation of breast cancer cells. Ciftci K; Su J; Trovitch PB J Pharm Pharmacol; 2003 Aug; 55(8):1135-41. PubMed ID: 12956904 [TBL] [Abstract][Full Text] [Related]
8. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569 [TBL] [Abstract][Full Text] [Related]
9. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544 [TBL] [Abstract][Full Text] [Related]
10. Downregulation of wild-type p53 protein by HER-2/neu mediated PI3K pathway activation in human breast cancer cells: its effect on cell proliferation and implication for therapy. Zheng L; Ren JQ; Li H; Kong ZL; Zhu HG Cell Res; 2004 Dec; 14(6):497-506. PubMed ID: 15625017 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of the PI3 kinase/Akt pathway enhances doxorubicin-induced apoptotic cell death in tumor cells in a p53-dependent manner. Fujiwara Y; Kawada K; Takano D; Tanimura S; Ozaki K; Kohno M Biochem Biophys Res Commun; 2006 Feb; 340(2):560-6. PubMed ID: 16378598 [TBL] [Abstract][Full Text] [Related]
12. Synergistic anti-cancer effects of grape seed extract and conventional cytotoxic agent doxorubicin against human breast carcinoma cells. Sharma G; Tyagi AK; Singh RP; Chan DC; Agarwal R Breast Cancer Res Treat; 2004 May; 85(1):1-12. PubMed ID: 15039593 [TBL] [Abstract][Full Text] [Related]
13. LY294002 induces p53-dependent apoptosis of SGC7901 gastric cancer cells. Xing CG; Zhu BS; Liu HH; Lin F; Yao HH; Liang ZQ; Qin ZH Acta Pharmacol Sin; 2008 Apr; 29(4):489-98. PubMed ID: 18358096 [TBL] [Abstract][Full Text] [Related]
14. GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis. Beurel E; Kornprobst M; Blivet-Van Eggelpoël MJ; Cadoret A; Capeau J; Desbois-Mouthon C Int J Oncol; 2005 Jul; 27(1):215-22. PubMed ID: 15942663 [TBL] [Abstract][Full Text] [Related]
15. AMPK Activation of Apoptotic Markers in Human Breast Cancer Cell Lines with Different p53 Backgrounds: MCF-7, MDA-MB-231 and T47D Cells. El-Masry OS; Brown BL; Dobson PRM Asian Pac J Cancer Prev; 2019 Dec; 20(12):3763-3770. PubMed ID: 31870119 [TBL] [Abstract][Full Text] [Related]
16. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft. Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847 [TBL] [Abstract][Full Text] [Related]
17. Effects of triptolide from Tripterygium wilfordii on ERalpha and p53 expression in two human breast cancer cell lines. Liu J; Jiang Z; Xiao J; Zhang Y; Lin S; Duan W; Yao J; Liu C; Huang X; Wang T; Liang Z; Wang R; Zhang S; Zhang L Phytomedicine; 2009 Nov; 16(11):1006-13. PubMed ID: 19524422 [TBL] [Abstract][Full Text] [Related]
18. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro. Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512 [TBL] [Abstract][Full Text] [Related]
19. PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis. Bender A; Opel D; Naumann I; Kappler R; Friedman L; von Schweinitz D; Debatin KM; Fulda S Oncogene; 2011 Jan; 30(4):494-503. PubMed ID: 20856197 [TBL] [Abstract][Full Text] [Related]
20. Combining flavopiridol with various signal transduction inhibitors. Witters LM; Myers A; Lipton A Oncol Rep; 2004 Mar; 11(3):693-8. PubMed ID: 14767524 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]